Metabolic tumor volume, cancer cell fraction, and prognosis – the case of T-cell/histiocyte-rich large B-cell lymphoma

References

• Ramsay AD, Smith WJ, Isaacson PG. T-cell-rich B-cell lymphoma. Am J Surg Pathol. 1988;12(6):433–443.
   PubMed Web of Science ®Google Scholar
• Delabie J, Vandenberghe E, Kennes C, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin’s disease, paragranuloma subtype. Am J Surg Pathol. 1992;16(1):37–48.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, et al. Pathology & genetics of tumours of haematopoietic and lymphoid tissues. 3rd ed. Lyon (France): IARC Press; 2001.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon (France): IARC Press; 2008.
   Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised. 4th ed. Lyon (France): IARC Press; 2017.
   Google Scholar
• Ohgami RS, Zhao S, Natkunam Y. Large B-cell lymphomas poor in B cells and rich in PD-1+ T cells can mimic T-cell lymphomas. Am J Clin Pathol. 2014;142(2):150–156.
   PubMed Web of Science ®Google Scholar
• Hartmann S, Döring C, Jakobus C, et al. Nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma – endpoints of a spectrum of one disease? PLoS One. 2013;8(11):e78812.
   PubMed Web of Science ®Google Scholar
• Achten R, Verhoef G, Vanuytsel L, et al. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol. 2002;20:1269–1277.
   PubMed Web of Science ®Google Scholar
• Bouabdallah R, Mounier N, Guettier C, et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol. 2003;21(7):1271–1277.
   PubMed Web of Science ®Google Scholar
• Aki H, Tuzuner N, Ongoren S, et al. T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma. Leuk Res. 2004;28(3):229–236.
   PubMed Web of Science ®Google Scholar
• El Weshi A, Akhtar S, Mourad WA, et al. T-cell/histiocyte-rich B-cell lymphoma: clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma. 2007;48(9):1764–1773.
   PubMed Web of Science ®Google Scholar
• Kim YS, Ji JH, Ko YH, et al. Matched-pair analysis comparing the outcomes of T cell/histiocyte-rich large B cell lymphoma and diffuse large B cell lymphoma in patients treated with rituximab-CHOP. Acta Haematol. 2014;131(3):156–161.
   PubMed Web of Science ®Google Scholar
• Kommalapati A, Tella SH, Go RS, et al. T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes. Br J Haematol. 2019;185(1):140–142.
   PubMed Web of Science ®Google Scholar
• Dührsen U, Müller S, Hertenstein B, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36(20):2024–2034.
   PubMed Web of Science ®Google Scholar
• Hüttmann A, Rekowski J, Müller SP, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial. Ann Hematol. 2019;98(4):897–907.
   PubMed Web of Science ®Google Scholar
• Schmitz C, Hüttmann A, Müller SP, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;123:25–36.
   Google Scholar
• Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood. 2012;120(25):4913–4920.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124(26):3870–3879.
   PubMed Web of Science ®Google Scholar
• Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–354.
   PubMed Web of Science ®Google Scholar
• Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE. J Nucl Med. 2018;59(1):1753.
   Google Scholar
• Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48(10):1626–1632.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–578.
   PubMed Web of Science ®Google Scholar
• Barber NA, Loberiza FR, Jr., Perry AM, et al. Does functional imaging distinguish nodular lymphocyte-predominant Hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma? Clin Lymphoma Myeloma Leuk. 2013;13(4):392–397.
   PubMed Web of Science ®Google Scholar
• Sasanelli M, Meignan M, Haioun C, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2017–2022.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43(7):1209–1219.
   PubMed Web of Science ®Google Scholar
• Chang CC, Cho SF, Chuang YW, et al. Prognostic significance of total metabolic tumor volume on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget. 2017;8(59):99587–99600.
   PubMedGoogle Scholar
• Toledano MN, Desbordes P, Banjar A, et al. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2018;45(5):680–688.
   PubMed Web of Science ®Google Scholar
• Bianconi E, Piovesan A, Facchin F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40(6):463–471.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24:5350–5357.
   PubMed Web of Science ®Google Scholar
• Lee AM, Clear AJ, Calaminici M, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. 2006;24(31):5052–5059.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159–2169.
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66(2):605–612.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313–2323.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24(5):679–690.
   PubMed Web of Science ®Google Scholar
• Grant C, Dunleavy K, Hessler J, et al. A phase II trial of alemtuzumab (Campath) with DA-EPOCH-R in relapsed or refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Blood. 2012;120(21):3709–3709.
   Google Scholar
• Hartmann S. From a pathologist’s point of view: histiocytic cells in Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Pathol Res Pract. 2015;211(12):901–904.
   PubMed Web of Science ®Google Scholar